'Bonds Are Back', For A Little While, At Least: Bank Of America
London: Investors piled back into bonds in the past week, directing the largest inflow into these funds for three months, although the pause in the bond market selloff will probably only be fleeting, Bank of America Merrill Lynch said on Friday.
The $6.3 billion inflow into bond funds in the week to Wednesday follows a torrid year for fixed income funds which saw $93 billion of redemptions, the largest outflow since 2008.
The week covered the New Year period, so many fund managers would have been on holiday. But those at their desks put money to work, with equity funds chalking up $5.5 billion inflows and emerging market debt funds their first inflow in nine weeks, of $1.9 billion.
"A wobble in risk assets would be no surprise in the coming weeks, with traders looking to play a pullback," wrote BAML's investment strategy team, led by Michael Hartnett in New York, in a note titled: "Bonds are Back".
US stocks and banks are among the most vulnerable to profit-taking, they said.
Uncertainty and unease surrounding US President-elect Donald Trump's inauguration, volatile trading in Chinese currency and money markets, and a potential US interest rate rise could all tempt investors to play safe in the coming weeks.
"(But) structurally, we remain bullish risk in the coming quarters," they wrote.
In the week to Wednesday, investors poured cash into high-yield bond funds for the sixth week in a row ($900 million) and a hefty $3.6 billion into investment-grade bond funds.
Gold funds saw an eighth consecutive weekly outflow, the longest losing streak in three years, while in equities Japanese funds posted the largest outflow in six weeks ($1.4 billion) but US funds pulled in $2.6 billion, BAML said.
-
Getting To Work Costs Women More | The Reason Why
It is not just about women paying more than men. It is about women paying much more in cities than in villages.
-
AI Bias In Investing Cannot Be Eliminated, But It Can Be Governed
Framing is a particularly important example as identical financial information presented in terms of gains rather than losses can lead an LLM to reach a different assessment.
-
Joining The Dots | Dark Skies, Steady Diya: Why Hope Holds This Diwali
With war, a weak rupee and foreign outflows weighing on sentiment, policymakers at the NDTV World Summit and market veterans at NDTV Profit Ignite: Diwali Edition offered the same advice: stay invested and filter out the noise.
-
The Curious Case of Equitas Small Finance Bank And A CEO Who Quit For Stock
PN Vasudevan believes persistent investor concerns over a perceived conflict of interest had become a governance overhang on Equitas Small Finance Bank's stock, even as the lender improved profitability and asset quality.
-
Talking Points This Week: AI Cash Burn, A Tiger Comeback And An India That Still Finds Its Own Path
India is not immune to higher oil or tighter global liquidity, yet its earnings base is broader, its domestic policy levers are still available.
-
Foreign Investors Own Half Of HDFC Bank and ICICI Bank. An LTCG Cut Could Matter Most Here
Foreign portfolio investors have US$115 billion parked in HDFC Bank, ICICI Bank. If the government cuts long-term capital gains tax, Jefferies says returning foreign money could land here first.
-
'Never Seen This Level Of Negativity': Sandeep Tandon Says The Next Rally May Be Closer Than You Think
Veteran investor Sandeep Tandon says foreign selling is easing, large-caps are due a comeback and mid-caps are crowded, while he turns positive on gold, power and pharma this Diwali.
-
Indians Stay With Family, Not In Hotels | The Reason Why
India still lacks enough clean, reliable and affordable hotels for budget-conscious travellers.
-
The Economic Imperative: Analysing The Material Driving Force Behind India-Canada Strategic Reset
This economic complementarity is further reinforced by deep institutional investment ties and talent mobility, which form the bedrock of the bilateral framework.
-
Medicine Pricing: Where Must Profit Stop?
India must confront excessive margins, hidden incentives and regulatory gaps that threaten the integrity of medicine.